Venglustat GZ402671 ( DrugBank: Venglustat )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	2
67	多発性嚢胞腎	1

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2021200023	27/10/2020	09/10/2020	A multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmaco ...	A multicenter, multinational, randomized, double-blind, placebo-controlled study to assess the effic ...	Tay-Sachs Disease, Sandhoff Disease	Drug: venglustat GZ402671 - Pharmaceutical form: tablet - Route of administration: oral Drug: placebo - ...	Tanaka Tomoyuki	NULL	Not Recruiting	>= 2age old	Not applicable	Both	77	Phase 3	Spain;United States;Brazil;Russian Federation;United Kingdom;Argentina;Austria;Czechia;Germany;Italy ...
2	NCT04221451 (ClinicalTrials.gov)	June 29, 2020	6/1/2020	A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmaco ...	A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Effic ...	Tay-Sachs Disease Sandhoff Disease	Drug: venglustat GZ402671;Drug: placebo	Genzyme, a Sanofi Company	NULL	Active, not recruiting	2 Years	N/A	All	74	Phase 3	United States;Argentina;Austria;Brazil;Czechia;France;Germany;Italy;Japan;Portugal;Russian Federatio ...

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04705051 (ClinicalTrials.gov)	February 9, 2021	8/1/2021	Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat	Multicenter, Open-label, Extension Study to Characterize the Long-term Efficacy and Safety of Early ...	Congenital Cystic Kidney Disease	Drug: Venglustat GZ402671	Sanofi	NULL	Terminated	18 Years	N/A	All	24	Phase 3	United States;Australia;Belgium;Germany;Japan;Korea, Republic of;Netherlands;Spain;France;Romania